Livzon Pharmaceutical products added to national medical insurance catalog

Livzon Pharmaceutical Group announced on December 7, 2025, that 194 of its products have been included in the National Medical Insurance Catalog (2025 Edition), effective January 1, 2026. This comprises 92 Class A and 102 Class B products. The company highlighted that none of its products were removed from the catalog.

Key inclusions involve the first-time addition of Livzon’s Aripiprazole Microspheres for injection, the expansion of coverage for Acetate Goserelin Microspheres for injection to include uterine fibroids, and the successful renewal of coverage for Eplarazole Sodium for injection. The new indication for Acetate Goserelin Microspheres for injection also covers prostate cancer and endometriosis (Stages I to IV). Eplarazole Sodium for injection's renewed coverage is for the prevention of stress-induced ulcers and digestive tract ulcers.

The company anticipates this expanded inclusion will positively impact future operating performance by broadening market reach and improving drug accessibility. However, Livzon Pharmaceutical Group notes that future sales remain subject to policy changes in the pharmaceutical industry and evolving market conditions.